Created at	Source	Raw Value	Validated value
Jan. 15, 2022, 10 a.m.	usa	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody
Oct. 16, 2021, 3 p.m.	usa	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;The incidence and serverity of any adverse reactions;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse reactions;The incidence and severity of unsolicited adverse reactions;The incidence of AESI observed;The incidence of SAE observed	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;The incidence and serverity of any adverse reactions;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse events;The incidence and serverity of solicited adverse reactions;The incidence and severity of unsolicited adverse reactions;The incidence of AESI observed;The incidence of SAE observed
Sept. 7, 2021, 2 a.m.	usa	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;The incidence and serverity of any adverse reactions/events;The incidence and serverity of solicited adverse reactions/events;The incidence and severity of unsolicited adverse reactions/events;The incidence of SAE and AESI observed	4-fold rise of anti- SARS-CoV-2 neutralizing antibody;4-fold rise of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;GMT of anti- SARS-CoV-2 neutralizing antibody;The incidence and serverity of any adverse reactions/events;The incidence and serverity of solicited adverse reactions/events;The incidence and severity of unsolicited adverse reactions/events;The incidence of SAE and AESI observed